drugset
drugset / Trial / NCT06926998

9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

NCT06926998 ↗

Phase 1/2 Not yet recruiting 260 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.

Timeline

Start
2025-04-15
Primary completion
2027-05-01
Completion
2027-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 9MW2821 Monoclonal antibody — Intravenous

Indications

female reproductive organ cancer